First Participant Enrolled in Study of ENT-01 for Parkinson's Disease Dementia 

The first participant is enrolled in a clinical study of ENT-01(Enterin, Philadelphia, PA), a compound designed to reverse neurologic symptoms associated with Parkinson’s disease dementia (PDD). The aim of the DEMET study, an open-label multi-center trial, is to enroll 30 participants with PDD over a 6-month period. Participants will receive escalating daily doses of ENT-01, followed by a fixed dose for 25 days. 

ENT-01 is a synthetic derivative of squalamine that is not absorbed into the bloodstream. Synthetic squalamine has been shown to prevent buildup and reduce toxicity of alpha-synuclein , which is implicated in the pathogenesis and progression of Parkinson's disease. 

Designed to displace membrane-bound, alpha-synuclein aggregates from neurons of the enteric nervous system, it is hoped that ENT-01 may improve neural signaling between the gut and the brain, stimulate gut motility, and alter afferent neural signaling from gut to brain.

In the phase 2a RASMET study (NCT03047629), ENT-01 improved both motor and non-motor symptoms of Parkinson’s disease and showed potential to modify disease progression.

Corticotropin Studied for Treatment of Amyotrophic Lateral Sclerosis

Previous News Article

Perampanel Monotherapy May Provide Seizure Freedom

Next News Article
This Month's Issue
The First Seizure

Christine Hung, MD

Women & Epilepsy

Jeffrey D. Kennedy, MD; and Melissa J. Chen, MD, MPH

Neuromuscular Notes: Rhabdomyolysis

Farah El-Sadi, MD; and Aaron Izenberg, MD, FRCPC